Abstract:
Changes in gut microbiota (GM) may be associated with the causation and progression of multiple liver diseases such as metabolic-associated liver disease, alcohol-associated liver disease (ALD), alcohol-associated hepatitis (AH), primary biliary cholangitis, primary sclerosing cholangitis, autoimmune liver disease, and most importantly, complications of cirrhosis and portal hypertension such as hepatic encephalopathy (HE), infection, and hepatocellular carcinoma. ALD includes simple steatosis, steatohepatitis, AH, cirrhosis, and acute-on-chronic liver failure. Alcohol consumption is associated with GM changes even before ALD development, and continued alcohol intake results in progressive dysbiosis and development of clinical events such as AH, infection, and HE. The composition and function of GM, specific changes in bacterial communities, and the functional metabolism of GM are affected in the spectrum of ALD, as revealed using high-throughput sequencing. It was reported in preliminary studies that modulation of disrupted GM improves adverse clinical events and ameliorates disease progression in ALD. In this review, we exhaustively discuss the preclinical and clinical studies on GM in ALD and critically discuss GM modulation and its effects based on various human and animal models of ALD.
摘要:
肠道微生物群(GM)的变化可能与多种肝病(如代谢相关肝病)的病因和进展有关。酒精相关性肝病(ALD),酒精相关肝炎(AH),原发性胆汁性胆管炎,原发性硬化性胆管炎,自身免疫性肝病,最重要的是,肝硬化和门静脉高压症的并发症,如肝性脑病(HE),感染,和肝细胞癌。ALD包括简单的脂肪变性,脂肪性肝炎,啊,肝硬化,和慢性急性肝衰竭。即使在ALD开发之前,酒精消费也与转基因变化有关,和持续的酒精摄入导致进行性生态失调和临床事件的发展,如AH,感染,和他。GM的组成和功能,细菌群落的特定变化,GM的功能代谢在ALD谱中受到影响,正如使用高通量测序所揭示的。据初步研究报道,调节破坏的GM可改善ALD中的不良临床事件并改善疾病进展。在这次审查中,我们详尽地讨论了ALD中GM的临床前和临床研究,并基于ALD的各种人类和动物模型批判性地讨论了GM调制及其作用。